🧬 Absci (ABSI): A Director Bought After a 5× Rally. Here's Why the Story May Still Be in Its Early Innings.

Inside the Eli Lilly $100 Million Backstop, Generative AI Drug Discovery, and Why We First Flagged Absci at $4.18

From Repeat Insider Buying to a 22% Short Interest, Here's Why the Investment Thesis Has Actually Become Stronger

Absci Corporation (NASDAQ: ABSI)
$11.54 (NASDAQ)
+0.31 (+2.76%)
As of July 6, 2026, 4:00 PM ET

🚀 FUNanc1al Atomic Statements

🗣️ Atomic Statement #1

"In biotechnology, today's balance sheet sometimes matters less than tomorrow's biology." — FUNanc1al

🗣️ Atomic Statement #2

"Clinical-stage biotech isn't valued by today's earnings. It's valued by tomorrow's probability." — FUNanc1al

🗣️ Atomic Statement #3

"The best insider purchases sometimes happen after big rallies—not before them." — FUNanc1al

💼 Executive Summary

Back in October 2025, when Absci traded around $4.18, we highlighted a wave of insider buying and argued that the market might be dramatically underestimating the company's long-term potential.

Less than a year later...

the stock has nearly tripled.

The science has progressed.

Strategic partnerships have expanded.

Institutions now own more than 80% of the company (vs 60% back then).

Most importantly...

another insider has purchased additional shares after that remarkable rally.

That's interesting.

Many executives buy because shares appear cheap.

Far fewer continue buying after the market has already rewarded investors.

That naturally raises a question:

Does management believe the story has only begun?

Let's investigate.

🧬 Meet Absci

Absci isn't another pharmaceutical company.

Nor is it another artificial intelligence company.

It's attempting to merge both worlds.

Founded in Vancouver, Washington, Absci has built what it describes as an Integrated Drug Creation™ platform—combining generative AI, laboratory biology, protein engineering, and high-throughput experimentation into a single drug-discovery engine.

Rather than spending years identifying promising antibody candidates through traditional trial-and-error...

Absci's platform attempts to design them computationally first...

then rapidly validate them experimentally.

If successful...

drug discovery itself becomes dramatically faster.

And perhaps dramatically cheaper.

🧪 Trigger #1: Another Insider Buy—This Time After a 5× Rally

This is where things become particularly interesting.

Many insider purchases occur after severe stock declines.

Absci's latest purchase occurred after a remarkable recovery.

Director Mary Szela recently acquired approximately:

✅ 12.900 shares

💰 Approximately $150,000

📈 Increasing her ownership meaningfully.

That matters.

Not because insiders are always correct.

They aren't.

But because this purchase comes after one of biotechnology's strongest recoveries over the past year.

Apparently...

she still believes there's room to run.

Why Mary Szela Matters

Mary Szela isn't simply another independent director.

She's spent decades leading some of healthcare's largest organizations.

Her résumé includes:

🏥 Former President of Abbott's multi-billion-dollar pharmaceutical business

🧬 Leadership roles across major biotechnology companies

💊 Deep expertise commercializing innovative therapies

In other words...

there is a remote possibility she understands biotechnology.

😂 A Little Boardroom Humor

Apparently...

after reviewing the clinical data...

she decided to review her brokerage account too.

🤝 Trigger #2: Wall Street Keeps Accumulating Shares

Institutional ownership has quietly climbed toward remarkable levels.

Today approximately 82–83% of Absci's outstanding shares are held by institutional investors (vs around 60% 8 months ago).

Major shareholders include firms such as:

FMR (owns 14.46% of shares outstanding; that's conviction!)

🏛 ARK Investment Management (8.80%)

🏛 BlackRock (7.22%)

🏛 Redmile Group (5.29%)

🏛 State Street

🏛 Vanguard

🏛 Advanced Micro Devices (yes, even AMD is in the house!)

Institutions aren't infallible.

Far from it.

But when ownership continues increasing while insiders are simultaneously buying...

investors should probably pay attention.

Professional Investors Continue Voting With Capital

Institutional investors generally possess:

Dedicated biotechnology analysts.

Scientific consultants.

Access to management.

Sophisticated valuation models.

That doesn't guarantee success.

It does mean they typically perform extensive due diligence before committing significant capital.

Seeing institutional ownership steadily increase while the company's pipeline matures is encouraging.

For Absci (ABSI)’s Institutional Ownership breakdown, 🔍 see here.

🔥 Trigger #3: A Short Interest That Could Become Fuel

Interestingly...

professional skeptics haven't disappeared.

Short interest currently remains elevated at roughly:

📉 22% of the float (vs 25% back in October 2025)

That creates an unusual setup.

If clinical results disappoint...

short sellers may ultimately prove correct.

If positive data continue emerging...

those same short sellers could eventually become future buyers.

That's exactly how powerful short squeezes develop.

Not because speculation suddenly appears...

but because reality begins changing faster than expectations.

🧠 Critical Food for Thought

One statistic we find particularly intriguing: when FUNanc1al first highlighted Absci in October 2025, roughly 24.5% of the float was sold short. Nearly a year later, short interest remains exceptionally elevated. That illustrates three important realities of investing... 1) Some bearish investors have undoubtedly lost significant money during Absci's remarkable rally. 2) Elevated short interest can become an unexpectedly powerful ally for long investors, as improving fundamentals may eventually force short covering and accelerate gains. 3) Short sellers are a permanent feature of financial markets. They may remain convinced they're right long after a stock begins proving otherwise. Contrarian investing isn't about betting against the crowd. It's about recognizing when the crowd may be mispricing reality.

💰 Trigger #4: Eli Lilly Already Performed Its Homework

One of Absci's strongest validation points receives surprisingly little attention.

Eli Lilly didn't merely announce a partnership.

The pharmaceutical giant (along with a number of other institutions including Adage, BVF Partners, Invus, Redmile, and other Wall Street powerhouses) invested approximately $100 million directly into Absci (following the pricing of an underwritten offering of ~13.5 million shares of its common stock at a price of $7.41 per share).

Absci intends to use the net proceeds from the offering to fund the advancement of ABS-201, Absci’s AI-designed anti-PRLR antibody program across androgenetic alopecia (pattern hair loss) and endometriosis, and for working capital and other general corporate purposes.

So Wall Street also invested.

That's important.

And large pharmaceutical companies don't casually deploy nine-figure investments.

Before doing so they typically perform:

🔬 Scientific due diligence

⚖ Intellectual-property review

📊 Commercial assessment

🧪 Pipeline evaluation

💰 Financial analysis

In other words...

Lilly had every opportunity to walk away.

Instead...

it invested fresh capital.

Why That Matters

Strategic partnerships come and go.

Strategic equity investments are rarer.

Eli Lilly effectively aligned itself with Absci's long-term success.

That doesn't eliminate clinical risk.

Nothing can.

But it does provide an unusually credible external validation of the platform's scientific potential.

Sometimes...

one sophisticated partner says more than a thousand enthusiastic press releases.

📊 Is Absci Expensive?

Compared with traditional biotechnology metrics...

yes.

Compared with mature pharmaceutical companies...

absolutely.

Compared with platform biotechnology companies attempting to reshape drug discovery...

the answer becomes considerably more nuanced.

Today's valuation largely reflects expectations.

Not earnings.

Not current cash flow.

Future optionality.

If Absci's platform consistently produces successful therapeutic candidates...

today's valuation may eventually appear inexpensive.

If the science disappoints...

the opposite may prove true.

Clinical-stage biotechnology has always been a probability business.

Absci simply happens to be trying to improve those probabilities using artificial intelligence.

🧬 Trigger #5: The Pipeline Is Finally Becoming Real

For years, investors primarily viewed Absci as an intriguing technology platform.

Today...

it increasingly resembles a biotechnology company with tangible therapeutic assets.

Its wholly owned pipeline now includes:

🧬 ABS-101 — Inflammatory bowel disease

💉 ABS-201 — Hair-loss treatment

🫀 Additional antibody programs advancing through discovery

Each program represents optionality.

Collectively...

they represent a diversified pipeline rather than a one-shot clinical gamble.

That distinction matters.

💇 Why ABS-201 May Become the Public Face of Absci

Hair loss isn't life-threatening.

It is, however, one of the world's largest unmet quality-of-life markets.

Millions of men and women actively seek:

• Better efficacy

• Faster results

• Fewer side effects

Absci believes ABS-201 may offer exactly that.

Early data suggest meaningful hair regrowth within approximately 65 days, positioning the program as one of the company's most visible wholly owned assets.

Whether those early findings ultimately translate into commercial success remains uncertain.

But investors understand hair loss.

It's tangible.

It's relatable.

And if clinical development continues progressing, ABS-201 could become the first program that introduces millions of consumers to the Absci story.

📈 Trigger #6: Financial Discipline Still Matters

Absci remains a clinical-stage biotechnology company.

Profitability is not the current objective.

Execution is.

Recent quarterly results reflected exactly that.

Highlights included:

💰 Strong liquidity [with cash and marketable securities of $125.7 million as of March 31, 2026, compared to $144.3 million as of December 31, 2025; and that was before the recent Eli Lilly-led $100 million offering].

📉 Disciplined operating expense management

🤝 Continued milestone revenue from partnerships

🧬 Ongoing investment across the therapeutic pipeline

Importantly...

the company continues funding innovation while maintaining a balance sheet capable of supporting near-term development objectives.

That's exactly what long-term investors hope to see at this stage.

 👉 Want the full picture? Dive into Absci (ABSI)’s financials here.

⚖️ Is Absci Becoming Less Speculative?

Not yet.

But perhaps...

less speculative than it was a year ago.

Consider the progression.

Back then:

• Platform promise

• Insider buying

• Institutional ownership around 60%

• Early partnerships

Today:

• Repeat insider buying

• Eli Lilly strategic investment

• Institutional ownership above 80%

• Clinical pipeline advancing

• Wholly owned assets entering human development

That's not proof of future success.

It is evidence that the investment thesis continues evolving in the right direction.

⚠️ Risks Investors Shouldn't Ignore

Biotechnology remains one of the market's highest-risk sectors.

Absci is no exception.

🧪 Clinical Failure

Every biotechnology company ultimately depends on science.

Promising early data can still fail during later-stage development.

Clinical setbacks remain the single largest investment risk.

💵 Cash Burn

Although Absci maintains a solid balance sheet today, clinical development is expensive.

Future capital raises remain possible if development timelines extend or new programs accelerate.

🤖 Artificial Intelligence Expectations

Artificial intelligence has become one of the market's favorite themes.

That creates opportunity.

It also creates unrealistic expectations.

Drug discovery remains extraordinarily difficult—even with better computational tools.

🏛 Partnership Concentration

Large pharmaceutical collaborations provide validation.

They can also create dependency.

Changes in strategic priorities at major partners could influence future revenue opportunities.

📉 Volatility

Clinical-stage biotechnology rarely moves gradually.

Expect meaningful volatility.

Investors should size positions accordingly.

🚀 What Could Change Sentiment?

Several developments could materially strengthen the investment case.

Successful clinical progress across ABS-101, ABS-201, or additional wholly owned programs would further validate the platform's ability to generate therapeutic candidates rather than simply technological promise.

New pharmaceutical partnerships—or expanded collaborations with existing partners such as Eli Lilly—could reinforce confidence in Absci's platform while providing additional non-dilutive capital.

Further insider buying by directors or senior executives would continue aligning management with shareholders.

Perhaps most importantly...

demonstrating that Generative AI consistently accelerates real-world drug discovery—not just theoretical research—could fundamentally change how investors value the company.

If that happens...

today's valuation could eventually look remarkably conservative.

🏆 FUNanc1al Value Verdict

Absci remains speculative.

Let's be perfectly clear.

Clinical-stage biotechnology always is.

Yet speculative investing and randomness are not the same thing.

Today investors aren't simply buying hope.

They're buying:

✅ A differentiated AI platform

✅ Multiple therapeutic programs

✅ One of the industry's strongest strategic partners

✅ Repeat insider buying

✅ Heavy institutional ownership

✅ Significant commercial optionality

For patient investors comfortable with biotechnology risk...

Absci remains one of the more compelling long-term speculative opportunities we've followed over the past year.

😂 A Little Biotech Humor

🤖 Artificial Intelligence

Apparently...

AI has now progressed from writing essays...

to designing antibodies.

Your move, biology.

🧬 Clinical Trials

Drug development is one of the few professions where "almost worked" still means...

back to the laboratory.

👩⚖️ Corporate Governance

When directors keep buying shares after the stock nearly triples...

perhaps they're reading something more interesting than Twitter.

📌 Signal Extract

"Clinical-stage biotech isn't valued by today's earnings. It's valued by tomorrow's probability." — FUNanc1al

🎯 High-Conviction Takeaway

"The market often mistakes volatility for risk. In biotechnology, they're rarely the same thing." — FUNanc1al

⚡ Quick Take / TL;DR

✅ Stock price nearly tripled since our original October 2025 coverage

✅ Director Mary Szela purchased approximately $150,000 of additional shares

✅ Eli Lilly and other biotech/Wall Street players invested approximately $100 million

✅ Institutional ownership approaching 83%

✅ Approximately 22% short interest

✅ Expanding wholly owned clinical pipeline

✅ Generative AI drug-discovery platform

FUNanc1al View

Absci remains a high-risk biotechnology investment.

It also remains one of the more intellectually fascinating platform companies we've covered.

The investment thesis hasn't merely survived.

It has matured.

❓ Frequently Asked Questions

Why is the recent insider purchase significant?

Because it occurred after the stock nearly tripled from our original October 2025 coverage. Insider buying following a major rally often reflects continuing conviction rather than opportunistic bargain hunting.

Why does Eli Lilly's investment matter?

Large pharmaceutical companies conduct extensive scientific, commercial, intellectual-property, and financial due diligence before making strategic equity investments. Lilly and other players' roughly $100 million investment provides meaningful external validation of Absci's platform.

Isn't Absci still speculative?

Absolutely.

Clinical-stage biotechnology always carries substantial risk.

However, the combination of strategic partnerships, insider buying, institutional ownership, and an advancing pipeline arguably makes today's investment case stronger than it was a year ago.

What is the biggest risk?

Clinical execution.

Ultimately, successful drug development—not artificial intelligence alone—will determine shareholder returns.

🌍 Food for Thought

The most interesting breakthroughs often sound improbable...

right up until they become obvious.

Electric cars.

Reusable rockets.

Protein folding.

Artificial intelligence.

Perhaps...

the next revolution won't simply discover better medicines.

It will discover them better.

👤 About Frédéric Marsanne

Frédéric Marsanne is the founder of FUNanc1al, where investing meets curiosity, science, technology, and humor.

An entrepreneur, investor, and long-time market observer, he writes original deep dives spanning biotechnology, artificial intelligence, behavioral finance, health, and emerging technologies. His goal is simple: connect the right dots, challenge conventional thinking, and help readers become better long-term decision-makers.

When not researching companies or writing, he's building Cl1Q, exploring new passions, and pursuing what he likes to call the FUNalization of life itself.

📝 Editorial Note

Every FUNanc1al article is grounded in human research, analysis, and editorial judgment. Modern AI tools may assist with research organization, editing, and presentation, but every opinion, conclusion, rating, and recommendation remains subject to human oversight and responsibility.

To learn more about how we research, write, and review every article, please visit our Editorial Process page.